22.73
-0.58(-2.49%)
Currency In USD
| Previous Close | 23.31 |
| Open | 23.31 |
| Day High | 23.59 |
| Day Low | 22.43 |
| 52-Week High | 27.64 |
| 52-Week Low | 11.16 |
| Volume | 557,422 |
| Average Volume | 695,893 |
| Market Cap | 1.05B |
| PE | -10.15 |
| EPS | -2.24 |
| Moving Average 50 Days | 24.88 |
| Moving Average 200 Days | 22.02 |
| Change | -0.58 |
If you invested $1000 in Pacira BioSciences, Inc. (PCRX) 10 years ago, it would be worth $341.09 as of July 15, 2025 at a share price of $22.73. Whereas If you bought $1000 worth of Pacira BioSciences, Inc. (PCRX) shares 5 years ago, it would be worth $395.44 as of July 15, 2025 at a share price of $22.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
GlobeNewswire Inc.
Jun 18, 2025 12:00 PM GMT
- Produced for Pacira by BBC StoryWorks Commercial Productions, The Next Frontier: Mark & Leah’s Story Highlights the Impact of Non-Opioid Solutions - BRISBANE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the
Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
GlobeNewswire Inc.
Jun 11, 2025 12:00 PM GMT
-- PCRX-201 demonstrated sustained clinical efficacy with improvements in pain, stiffness, and function for up to three years – BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
GlobeNewswire Inc.
May 15, 2025 12:00 PM GMT
-- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 – -- An oral presentation of the data to be featured at the ASGCT Annual Meeting -- BRISB